Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet

Group 1 - 10x Genomics (TXG) closed at $8.86, with a 7.1% gain over the past four weeks, and a mean price target of $12.68 suggests a 43.1% upside potential [1] - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.05, indicating variability among analysts; the lowest estimate is $6.50 (26.6% decline), while the highest is $18 (103.2% increase) [2] - Analysts show strong agreement on TXG's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for TXG's current year earnings has increased by 17.8%, with seven estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]